In the MyPathway trial, anti‐HER2 monoclonal antibodies trastuzumab in combination with pertuzumab reported a 21% [95% CI: 5%–51%] ORR for patients with NSCLC (n = 12).25 Here, ERBB2 is linked to non-small cell lung carcinoma.